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Background: To assess postoperative complications, clinical outcome and histological findings in patients
undergoing intraoperative radiotherapy with low energy x-rays for early breast cancer.
Methods: We retrospectively analysed data of 208 women who underwent intraoperative irradiation during breast
conserving surgery (BCS) between 2002 and 2007. Demographic, clinical and surgical parameters as well as
short-term complications within the first postoperative week and histological findings were evaluated. Toxicities
were assessed using the CTC/EORTC Score.
Results: Postoperative complications were rare and the immediate toxicity low, without any grade 3/4 acute
toxicity. The most frequent postoperative side effects were suggillation (24%) and palpable seroma (17.3%). In 78.6%
of the axillary seroma and in 25% of the breast seroma a needle aspiration was inevitable. Erythema grade I-II of the
breast was found in 27 women (13%); whereas in 7 patients (3.4%), mastitis was confirmed. In 57.7% of the cases,
the pathological assessment revealed ductal invasive breast cancer and tumour size ranged between 0.1 and
4.5 cm (mean = 1.6 cm).
Conclusion: IORT using IntrabeamW during BCS is safe, although it is associated with postoperative adverse events
such as seroma. These should be mentioned and explained to women in detail during the preoperative discussion.
This explicitly clinical description is useful for daily clinical practice; especially for giving a detailed analysis of the
postoperative side effects during preoperative counselling.
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Breast cancer is the most common malignant neoplasm in
women and the third cause of death in Europe [1]. Treat-
ment of early breast cancer consists of breast conserving
surgery (BCS), typically in combination with axillary sen-
tinel lymph node biopsy (SNB) followed by external beam
whole breast radiotherapy (EBRT). Furthermore, chemo-
therapy, endocrine and targeted therapies play an import-
ant role in the treatment of breast cancer. The therapeutic
approaches chosen depend on the patient, as well as the* Correspondence: benjamin.tuschy@umm.de
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reproduction in any medium, provided the orclinical and pathological parameters of the tumour; such
as stage, presence of hormone receptors and other bio-
logical characteristics [1].
Over time, radiotherapy techniques have become more
sophisticated, and by applying an additional tumour bed
boost of 10–20 Gy the risk of a local relapse could be
further reduced [2]. In case of an externally delivered
boost the risk of missing the target volume is considered
to be 20-90% [2]. Intraoperative radiotherapy (IORT) is
able to minimise this risk of missing the target and to
shorten the interval between tumour excision and the
beginning of the adjuvant radiotherapy [3].
There are various techniques for applying an IORT. Li-
near accelerators, brachytherapy or novel mobile devicesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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used for intraoperative irradiation [2].
At the University Medical Centre Mannheim, the mo-
bile device IntrabeamW (Carl Zeiss Surgical, Oberkochen,
Germany) a miniature x-ray source with 50 kV maximum
has been used for tumour bed boost radiation during BCS
in selected breast cancer patients since February 2002.
Besides applying IORT as a boost, Vaydia et al. showed
that IORT as a sole treatment in a low risk collective
(women with primary unifocal ductal invasive breast
cancer, aged 45 years or older) is non inferior to an EBRT
regarding local recurrence [4].
A systematic review of scientific literature dealing with
the efficacy and safety of IORT showed that IORT is not
inferior to a conventional treatment. Also, the survival in
patients treated with IORT seems to be similar to women
who received conventional irradiation [1]. Furthermore,
advantages like higher dose homogeneity, exclusion of
non-affected structures from the radiation area and the
avoidance of delay between surgery and radiotherapy out-
line IORT as a promising and probably steadily increasing
alternative in the treatment of early breast cancer [1]. Be-
side these advantages, long term toxicity affecting quality
of life negatively is very important for women undergoing
BCS with IORT [5]. Sperk et al. showed that long term
toxicity after IORT is low. Especially patients treated with
IORT alone have about half the risk for developing higher
grade toxicities as compared to standard whole breast
radiotherapy [6].
Reviewing the literature, there are a few studies dealing
with the late toxicity of IORT. However, studies looking at
short-term complications are rare, especially after using
the IntrabeamW system [6-10].
Hence, this is the largest series dealing with immediate
postoperative complications in women treated with IORT
using IntrabeamW.
The aim of this investigation was to evaluate the peri-
operative toxicity, the clinical outcome and the histological
findings in women undergoing IORT using low kilovoltage
x-rays.
Methods
Between February 2002 and April 2007, a total of 208
women were treated with IORT using the mobile device
IntrabeamW (Carl Zeiss Surgical, Oberkochen, Germany)
during BCS at the University Medical Centre Mannheim,
Germany. In 147 women (70.7%), IORT was applied as a
boost irradiation while 61 patients (29.3%) received IORT
without an additional EBRT.
This allocation was due to participation of women in the
prospective international TARGIT-Trial, in which IORT as
a sole treatment in a low risk collective was investigated [4].
The IntrabeamW system is composed of a miniature
(1.6 kg) x-ray source having a probe of 10cm length and3.2 mm diameter, a set of spherical applicators from 1.5
to 5.0 cm in diameter, a carrier system and a control
unit. Accelerated electrons aimed on a gold target pro-
duce a spherical radiation field with an isotropic dose
distribution around the tip of the probe. Using this
method low energy x-rays (50 kV) are generated. Due to
the steep dose fall-off, this mobile device can be used in
unmodified operating rooms. Prior to use, mechanical
stability, dose rate and homogeneity of the emitted ra-
diation were checked in detail. The patients received a
perioperative intravenous single shot antibiotic treat-
ment with 1.5 g cefuroxime. After informed consent was
given from every woman in whom radiotherapy was
planned, the surgical and radiotherapeutic procedures
were performed as a standardized operating procedure.
Histological findings were assessed at the Department of
Pathology at the University Medical Centre Mannheim.
Demographic and surgical parameters as stated below
were analysed retrospectively. Clinical outcomes as well as
cosmetic results were evaluated every day during the first
week after surgery. Toxicities were assessed using the
CTC 4.0/EORTC Score. Other findings were documented
without grading. This findings include: haematoma/suggi-
llation, palpable seroma, mastitis, the necessity of thera-
peutic application of antibiotics, prolonged prophylactic
antibiotic therapy for three days, breast induration, indu-
ration of the tumour bed, retraction of the scar, postoperative
fever, pre- and postoperative blood count and the usage of
postoperative pain relievers.
All data were collected in an Excel™ (Microsoft Cor-
poration, Redmond, Seattle, USA) datasheet. After care-
ful check for faulty entries and extreme values, the data
were transferred into SPSS (SPSSW version 17.0, SPSS
Inc. Chicago, USA) for statistical analysis. Quantitative data
were presented as median and range, qualitative data as
frequencies. All computations were done using the SPSS
statistics software.
Results
In general there were no severe postoperative complica-
tions and the observed acute toxicity after IORT was
low, without any grade 3/4 acute toxicity. A total of 208
women aged 30 to 95 years (mean = 63 years) with early
breast cancer were treated with IORT between 2002 and
2007. The body mass index (BMI) of the study collective
ranged between 18 and 57 (mean = 27); 22 women
(10.6%) suffered from diabetes mellitus; 34 (16.3%) were
smokers. There were no significant differences regarding
short-term complications within the first postoperative
week between women in which IORT was applied as a
boost irradiation and the women who received IORT
without additional EBRT.
Surgical parameters of the patients are presented in
Table 1 in detail.
Table 1 Surgical parameters of women undergoing IORT
Study group
(n = 208)
Type of axillary surgery
- SNB 109 (52.4%)
- ALNE (primary or after SNB) 115 (55.3%)
Duration of surgery (min)
- < 60 1 (0.5%)
- 60 – 90 6 (2.9%)
- 90 – 120 35 (16.8%)
- 120 – 180 126 (60.6%)
- > 180 40 (19.2%)
Intraoperative antibiotic treatment 194 (93.3%)
Radiation treatment
- IORT only 61 (29.3%)
- IORT Boost 147 (70.7%)
Duration of irradiation (min) mean 30 (10–60)
Data are given as n (%).
SNB = sentinel node biopsy, ALNE = axillary lymph node excision.
Table 2 Tumour characteristics
Parameter Study group
(n = 208)
Primary tumour location – n (%)
- left superior lateral 61 (29.3%)
- left superior medial 25 (12.0%)
- left inferior lateral 9 (4.3%)
- left inferior medial 8 (3.8%)
- right superior lateral 63 (30.3%)
- right superior medial 12 (5.8%)
- right inferior lateral 7 (3.4%)
- right inferior medial 9 (4.3%)
- unknown 14 (6.8%)
Tumor size (cm) 1.6 (0.1 – 4.5)
Nodal involvement
- pN0 148 (71.2%)
- pN1mic 35 (16.8%)
- pN1a 6 (2.9%)
- pN2a 1 (0.5%)
- pN3a 1 (0.5%)
- unknown 17 (8.2%)
Metastasis
- M0 193 (92.8%)
- M1 6 (2.9%)
- unknown 9 (4.3%)
Histology – n (%)
- Ductal-invasive 120 (57.7%)
- Lobular-invasive 41 (19.7%)
- Tubulo/lobular-invasive 16 (7.7%)
- Other 31 (14.9%)
Grading - n (%)
- 1 33 (15.9%)
- 2 132 (63.5%)
- 3 36 (17.3%)
- unknown 7 (3.3%)
Lymphangioinvasion
- L0 22 (10.6%)
- L1 132 (63.5%)
- unknown 54 (26.0%)
Hormone receptors (ER; PR)
- positive 182 (87.5%)
- negative 26 (12.5%)
HER-2/neu
- positive 21 (10.1%)
- negative 181 (87.0%)
- unknown 6 (2.9%)
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vealed ductal breast cancer, and tumour size ranged be-
tween 0.1 and 4.5 cm (mean = 1.6 cm). In most cases,
breast cancer occurred in the upper outer quadrant of
the breast, in 49.4% the left breast was affected and in
43.8% the cancer occurred in the right side. The tumour
localisation could not be assigned clearly to one single
quadrant in 14 patients (6.7%). In 6 women (2.9%), me-
tastases were detected by abdominal ultrasound, thoracic
x-ray or bone scan during hospital stay. In 148 patients
(71.2%), the assessment of the sentinel node revealed a
tumour-free node. Histological findings and tumour
localisations are depicted in Table 2.
In 206 women (99%), a wound drainage was inserted
during surgery, and in 151 cases (72.6%) it was left
for three to five days. The most frequent postoperative
side effects were haematomas/suggillation and palpable
seroma. Haematomas/suggillations were found in 50 cases
(24%) in the breast and in 22 patients (10.6%) in the axilla.
A surgical revision due to a haematoma or insufficient
postoperative haemostasis was necessary in 3 cases (1.4%).
28 women (13.5%) developed a seroma located in the
axilla; in 8 cases (3.8%) palpable seroma emerged in the
breast. A needle aspiration was necessary in 2 cases (25%)
with breast seroma and in 22 cases (78.6%) with seroma
located in the axilla. Erythema grade I-II arose in 27
women (13%), none of them were classified as grade III or
IV. Seventy-five patients (36.1%) received postoperative
therapeutic antibiotics, in addition to the prolonged
prophylactic antibiotic therapy for three days. In only 7
women (3.4%), the diagnosis of mastitis was confirmed.
Fever, which was defined as elevated body temperature
Table 2 Tumour characteristics (Continued)
EIC
- no 197 (94.7%)
- yes 11 (5.3%)
Data are given as n (%), mean and range.
ER = Estrogen receptor; PR = Progesterone receptor; EIC = extensive
intraductal component.




- before surgery 13.8 (9.1 – 18.0)
- after surgery (day 1) 12.7 (7.9 – 15.9)
- difference −1.0 (−0.8 – 4.7)
Leukocytes (109/l)
- before surgery 6.8 (3.5 – 13.3)
- after surgery 8.3 (2.8 – 19.1)
- difference +1.5 (−7.0 – 7.8)
Drainage – n (%) 206 (99.0%)
Duration of drainage (in days)
- < 3 d 47 (22.6%)
- 3–5 d 151 (72.6%)
- > 5 d 7 (3.4%)
- unknown 3 (1.5%)
Palpable Seroma breast – n (%) 8 (3.8%)
- needle aspiration 2 (25.0%)
- no needle aspiration 6 (75%)
Palpable Seroma axilla – n (%) 28 (13.5%)
- needle aspiration once 11 (39.3%)
- needle aspiration twice 6 (21.4%)
- needle aspiration three times 5 (17.9%)
- no needle aspiration 6 (21.4%)
Haematoma/suggillation breast – n (%) 50 (24.0%)
- surgical revision 2 (1.0%)
Haematom axilla – n (%) 22 (10.6%)
- surgical revision 1 (0.5%)
Inconspicuous woundhealing– n (%) 86 (41.3%)
Erythema Grade I-II – n (%) 27 (13.0%)
Mastitis – n (%) 7 (3.4%)
Fever – n (%) 22 (10.6%)
Therapeutic antibiotic treatment – n (%) 75 (36.1%)
Induration toumor bed – n (%) 17 (8.2%)
Retraction of the scar– n (%) 2 (1.0%)
Postoperative pain reliever -n (%)
- on demand 28 (13.5%)
- regular 79 (38.0%)
Nausea postop– n (%) 3 (1.4%)
Duration of hospital stay (in days)
- < 7 12 (5.8%)
- 7 – 10 126 (60.5%)
- > 10 70 (33.7%)
Data are given as median (range) or n (%).
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eter, occurred in 22 women (10.6%) within the first seven
postoperative days [11]. A further detailed description of
postoperative events is depicted in Table 3.
Discussion
In recent years, breast cancer mortality rates in the western
world have declined as a result of extensive research
leading to advances in diagnostics and treatment. BCS
radiotherapy, as an inherent part of interdisciplinary
treatment, has become more sophisticated by delivering
higher effective radiation doses without increasing side
effects [1].
An additive irradiation of the tumour bed, as the area
in which more than 90% of the in breast recurrences
occur, reduces the local recurrence rate especially in
young high risk patients [12]. This boost can by applied
as an IORT, which is not inferior to the conventional
treatment with respect to local control, safety and cos-
metic results [1,6].
Besides the IntrabeamW System, mobile linear accelera-
tors delivering electrons at different energies (Novac7
(Hitesys Srl, Latina, Italy), Liac (Info & Tech, Roma, Italy)
are being used for intraoperative electron beam radiation
therapy (IOERT) in women suffering from breast cancer
[10].
For these devices, collimators ranging form 3 to 12 cm
were used to deliver electron beams. A radiation protec-
tion composed of a lead shielding has to be placed in
the operating theatre before the beginning of radiation
treatment [10].
Several investigations focused on the late toxicity and
oncological aspects of IORT and IOERT in women suffe-
ring from breast cancer; they found that acute toxicity and
postoperative complications are rare, especially when
using the IntrabeamW System [4,7,10,12-14].
A literature review finds that the most frequent side
effects after IORT were seroma, wound healing disorders
and fibrosis [1]. Veronesi et al. investigated a total of 590
women suffering unifocal breast cancer of less than 2.5 cm
in diameter after an IOERT by using a mobile linear accel-
erator (Nocac7) as mentioned above [10]. In 574 women
IOERT was applied as a sole radiation treatment while 16
patients received IOERT as an anticipated boost followed
by external radiotherapy. Early complications were evalu-
ated four weeks after surgery. 0.8% of these women showed
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2.5% had to undergo fine needle aspirations due to
liponecrosis within one month after surgery.
Ivaldi et al. evaluated the acute toxicity after an IOERT
boost of 12 Gy during breast conserving surgery followed
by hypofractionated external whole breast radiotherapy
(HEBRT) with a total dose of 37.05 Gy [15]. The acute
toxicity was evaluated at the end of the external beam
radiotherapy. Nine women (4.4%) developed liponecroses
within 4 weeks, one woman within 6 weeks and one of
them could not receive HEBRT because of a long lasting
delay in wound healing after IOERT. Erythema and dry
desquamation, as the most frequent early toxicity, were
classified as mild by 67% of the patients. The peak of
severe skin reactions occurred at the end of the external
irradiation [15].
We published a series of 84 women treated with IORT
as a boost using IntrabeamW in a prospective study. Acute
toxicity and the cosmetic result were evaluated after sur-
gery at one week, and one, two and four to six months [8].
In this investigation, the mean tumour size was 15 mm
and the most frequently used applicator size was 4.5 cm.
One week after surgery, IORT erythema occurred in 3% of
the patients and 2% of the women suffered delayed wound
healing. In 2%, the diagnosis mastitis was confirmed. The
most frequent complication after one week was haemato-
seroma, found in 6% of the patients. In a further investiga-
tion published by Kraus-Tiefenbacher et al. in which 57
women were treated with IntrabeamW, 5% suffered wound
healing disorder and 3% developed a haematoma requiring
needle aspiration. Erythema of the breast one day after
surgery was observed in one case (1.7%) [12].
It is difficult to compare our results with the results of
Veronesi and Ivaldi [10,15]. In these investigations patients
were treated with IOERT and the immediate postoperative
outcome was not evaluated at all.
Studies dealing with short-term complications after the
usage of the IntrabeamW system are scarce and their sam-
ple sizes are small. For example, Kraus- Tiefenbacher’s
study only included 84 women (our’s included 208).
The incidence of mastitis was the same as mentioned in
studies with a smaller collective. This relatively low in-
cidence of wound infections in studies can probably be
attributed to the routine use of prophylactic antibiotic
treatment. Our results confirm a prospective trial by
Joseph et al., which emphasises the necessity of prophylac-
tic antibiotic treatment in patients undergoing IORT [16].
This investigation, which included 35 women, found that
the rate of early breast infections could be diminished
from 25% to 11% by the usage of prophylactic antibiotics.
However, the incidence of breast haematoma or seroma
(17%) and axillary lymphocoele (29%) requiring additional
therapy (e.g. aspiration) remains high. In our investigation,
a needle aspiration was necessary in 25% of the seromasin the breast and 82% of the seromas located in the axilla.
In a previous study we showed that the rate of clinically
palpable seromas and seromas requiring needle aspiration
was not increased after BCS with IORT compared to con-
ventional EBRT [17]. Furthermore the high incidence of
palpable axillary seromas in our investigation is not an
immediate consequence of the IORT. Nevertheless, the
potential necessity of a postoperative needle aspirations
after breast surgery combined with IORT should be
discussed in detail with the women prior to surgery. post-
operative erythema after IORT our results differ to the in-
vestigation from Kraus-Tiefenbacher et al. [8]. In this
investigation an erythema occurred in 3% in contrast to
13% in our study. The reason for the different incidences
of postoperative complications does not seem to be the
size of the tumour, which was 15 mm in the study of
Kraus-Tiefenbacher et al., compared to 16 mm in our
study.
In investigations of acute toxicity after IORT using
IntrabeamW, the incidence of seroma and haematoma
was lower than in our investigation. A reason for the
higher incidences in our study may be the timing of cli-
nical evaluation. In our trial, a daily assessment of the
breast was performed after BCS and IORT. But in other
studies, the first postoperative evaluation was performed
after seven days when the initial acute phase reaction
following surgery had declined. Furthermore, residues of
haematomas and wound fluid in the breast can be ob-
served immediately after surgery, but are (particularly)
absorbed after a few days.
However, the comparison of the few existing studies
dealing with acute toxicity after IORT seems to be difficult
because different investigators had different endpoints,
different classifications and different time points of eva-
luating the toxicities.Conclusion
These results verify the safety of IORT with low energy
x-rays with regard to the acute toxicity. This investigation
is the largest series dealing with perioperative toxicity after
IORT with the IntrabeamW system giving a detailed de-
scription of the immediate postoperative outcome. These
results are useful for daily clinical practice, especially for
pre- operative counselling.
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